To further validate the relationships between KK-LC-1, MAL2, and MUC1 expression, we detected the expression of KK-LC-1 (Fig. 6A), MAL2, and MUC1 in 126 triple-negative breast cancer clinical samples. Here, CT83 is linked to triple-negative breast carcinoma.